Ever­est Med­i­cines be­gins pro­duc­tion at its new $129M+ mR­NA vac­cine man­u­fac­tur­ing fa­cil­i­ty in Chi­na

The Chi­na-based biotech Ever­est Med­i­cines has opened the doors to a new man­u­fac­tur­ing fa­cil­i­ty to pro­duce mR­NA-based vac­cines.

Ever­est’s new fa­cil­i­ty, which is lo­cat­ed just to the west of Shang­hai in Ji­ashan, Zhe­jiang Province, is around 58,000 square me­ters, or an es­ti­mat­ed 624,306 square feet, and had an in­vest­ment of more than RMB 900 mil­lion ($129 mil­lion). The man­u­fac­tur­ing fa­cil­i­ty plans to pro­duce around 700 mil­lion dos­es of mR­NA vac­cine an­nu­al­ly.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.